Brief: Olema Oncology Receives FDA Fast Track Designation For OP-1250 For The Treatment Of ER+ / HER2- Metastatic Breast Cancer
21/07/2022 12:47
July 21 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY RECEIVES FDA FAST TRACK DESIGNATION FOR
OP-1250
FOR THE TREATMENT OF ER+ / HER2- METASTATIC BREAST CANCER
Source text for Eikon: ID:nGNX2QtmPL
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Oncology
See all newsBrief: Olema Pharmaceuticals Changes Corporate Name To Olema Oncology, Effective Today
Olema Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary
Olema Pharma Q3 net loss widens on higher costs
Brief: Olema Pharmaceuticals Q3 Net Income USD -73.599 Million
Olema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary